Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00222144 | Study of Gleevec and Taxotere in Recurrent Non-Small Cell Lung Cancer | PHASE2 | COMPLETED | 23 | — | — | Sep 1, 2004 | Nov 1, 2010 | Aug 7, 2012 | 2 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Gleevec and Taxotere |
| Name | Type | Description |
|---|---|---|
| Gleevec and Taxotere | DRUG | Gleevec 600 mg QD for 12 months Taxotere IV 30 mg/m2 on day 1, 8 and 15 |
Inclusion Criteria: * One prior chemotherapy treatment: use of single chemotherapy or a regimen containing more than one drug. Regimen must have a platinum agent (cisplatin or carboplatin). Prior biological treatment won't be counted as chemotherapy treatment. Chemoradiation or prior induction or a...